Patents Assigned to Juno Therapeutics, Inc.
  • Publication number: 20240115612
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Application
    Filed: November 15, 2023
    Publication date: April 11, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
  • Patent number: 11952408
    Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 9, 2024
    Assignees: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Cameron Brandt, Brian Belmont, Christopher Borges, Stephen Michael Burleigh, Alexandra Croft, Stephen Jacob Goldfless, David Jeffrey Huss, Yue Jiang, Timothy G. Johnstone, David Koppstein, Hieu Nguyen, Christopher Heath Nye, Haley Peper, Blythe D. Sather, Sonia Timberlake, Dean Y. Toy, Queenie Vong, Gordon Grant Welstead, James Sissons
  • Publication number: 20240108654
    Abstract: Provided herein are methods, compositions and uses involving T cell therapies, such as adoptive T cell therapy, and an inhibitor of a Diacylglycerol kinase (DGK). The provided methods, compositions and uses include those involving the administration or use of one or more DGK inhibitors (DGKi) in a combination therapy with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR) or T cell receptor (TCR).
    Type: Application
    Filed: March 2, 2022
    Publication date: April 4, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: David G. KUGLER, Jim QIN, Alison MAIER, Richard OLSON, Michael WICHROSKI, Upender VELAPARTHI, Chetan Padmakar DARNE, Bireshwar DASGUPTA, Denise Christine GRUNENFELDER, Jayakumar Sankara WARRIER, Hasibur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Pallavur SIVAKUMAR
  • Patent number: 11944647
    Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: April 2, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
  • Publication number: 20240103012
    Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.
    Type: Application
    Filed: September 27, 2023
    Publication date: March 28, 2024
    Applicants: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research Center
    Inventors: He LI, Mark J. GILBERT, David MALONEY, Stanley R. RIDDELL, Cameron J. TURTLE
  • Publication number: 20240084253
    Abstract: Provided herein are methods for screening for one or more activity of a recombinant receptor, including recombinant receptors containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR). The methods include assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule that is responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells or plurality of cells for one or more property or activity. The methods can be high-throughput. Also provided are reporter cells, cell compositions, nucleic acids and kits for use in the methods.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 14, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Rupesh AMIN, Aye CHEN
  • Publication number: 20240076617
    Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 7, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Mirna MUJACIC, Ayu RAHARDJO
  • Patent number: 11919970
    Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 5, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
  • Publication number: 20240066122
    Abstract: Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration.
    Type: Application
    Filed: October 20, 2023
    Publication date: February 29, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventor: Mark J. GILBERT
  • Publication number: 20240053250
    Abstract: Provided are methods for flow cytometry analysis, including the setting and use of static gating thresholds separating positive fluorescence from negative fluorescence for each fluorescence channel in the assay.
    Type: Application
    Filed: December 15, 2021
    Publication date: February 15, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Rebecca BRUNETTE, Ryan P. LARSON, Kevin HAWKINS
  • Patent number: 11896615
    Abstract: Provided are methods of treatment involving immunotherapy, such as T cell therapy, and administration of a tryptophan metabolism and/or kynurenine pathway modulator. In some embodiments, the method includes a combination therapy that involves administration of engineered T cells, such as chimeric antigen receptor (CAR)-expressing cells, and a tryptophan metabolism and/or kynurenine pathway modulator, such as an inhibitor of an enzyme. Also provided are engineered cells in which the expression of a molecule involved in the kynurenine pathway is modified. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration to subjects, nucleic acids and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, activity, outcome, function, response, persistence, expansion and/or proliferation of cells for adoptive cell therapy.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 13, 2024
    Assignee: Juno Therapeutics, Inc.
    Inventors: Michael Ports, Evan Paul Thomas, Hyam I. Levitsky
  • Publication number: 20240041929
    Abstract: Provided are chimeric antigen receptors (CARs), which contain extracellular antigen-binding domains that bind to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and B-cell maturation antigen (BCMA). The disclosure further relates to genetically engineered cells expressing such CARs, and uses thereof in adoptive cell therapy.
    Type: Application
    Filed: August 4, 2023
    Publication date: February 8, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Brian Joshua BELMONT, Kimberly HARRINGTON, Cyr Clovis Chua DE IMUS, Jon Christopher JONES, Eric William JEFFERY, Yeonjoo OH, Heather STRIEGEL
  • Publication number: 20240018256
    Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Yan CHEN, Steven M. Shamah, Csaba Pazmany, Jui DUTTA-SIMMONS
  • Publication number: 20240018268
    Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-CD19 antibody moieties, in particular, anti-CD19 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-CD19 CART cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.
    Type: Application
    Filed: July 29, 2017
    Publication date: January 18, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Collin HAUSKINS, Mark D. HEIPEL, Claire L. SUTHERLAND, Taher SATHALIYA, Jeff SMITH
  • Publication number: 20240016840
    Abstract: The present disclosure relates to methods, compositions and uses involving immunotherapies and inhibitors of a target protein tyrosine kinase in which the kinase is not IL-2-inducible T cell kinase (ITK) and/or is selected from Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC), BMX non-receptor tyrosine kinase (Etk), TXK tyrosine kinase (TXK) and/or receptor tyrosine-protein kinase ErbB4 (ErbB4). The provided methods, compositions and uses include administration of one or more such inhibitor with another agent, such as an immunotherapeutic agent targeting T cells and/or genetically engineered T cells, such as CAR-expressing T cells. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration, nucleic acids, articles of manufacture and kits.
    Type: Application
    Filed: January 17, 2023
    Publication date: January 18, 2024
    Applicants: Juno Therapeutics, Inc., Acerta Pharma, B.V.
    Inventors: Michael Ports, Jim Qin, Ruth Salmon, Oleksandr Baturevych
  • Publication number: 20240011051
    Abstract: Provided are methods, systems, and kits for cell processing, e.g., for therapeutic use, such as for adoptive cell therapy. The provided methods include transduction methods, in which cells and virus are incubated under conditions that result in transduction of the cells with a viral vector. The incubation in some embodiments is carried out in an internal cavity of a generally rigid centrifugal chamber, such as a cylindrical chamber made of hard plastic, the cavity of which may have a variable volume. The methods include other processing steps, including those carried out in such a chamber, including washing, selection, isolation, culture, and formulation. In particular, the disclosure relates to method providing advantages over available processing methods, such as available methods for large-scale processing. Such advantages include, for example, reduced cost, streamlining, increased efficacy, increased safety, and increased reproducibility among different subjects and conditions.
    Type: Application
    Filed: September 21, 2023
    Publication date: January 11, 2024
    Applicant: Juno Therapeutics, Inc.
    Inventors: Ryan L. CRISMAN, Chris RAMSBORG, Travis WOOD
  • Patent number: 11851678
    Abstract: Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naive-like CD4+ T cells to naive-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: December 26, 2023
    Assignee: Juno Therapeutics, Inc.
    Inventors: Mirna Mujacic, Ayu Rahardjo
  • Patent number: 11851679
    Abstract: Provided herein are reporter T-cells containing a reporter operably linked to the Nur77 locus. Also provided are methods for screening for an activity of a recombinant receptor, including those containing an extracellular antigen-binding domain and an intracellular signaling domain, such as a chimeric antigen receptor (CAR), including assessing activity of a cell expressing the recombinant receptor based on a detectable expression of a reporter molecule responsive to a signal through the intracellular signaling region of the recombinant receptor. In some embodiments, the activity assessed is an antigen-dependent or an antigen-independent activity. In some embodiments, the methods can be used to screen a plurality of reporter cells each containing a nucleic acid molecule encoding a candidate recombinant receptor, e.g. CAR, and assessing such cells for one or more property or activity. The methods can be high-throughput.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: December 26, 2023
    Assignee: Juno Therapeutics, Inc.
    Inventors: Rupesh Amin, Aye Chen
  • Publication number: 20230398148
    Abstract: Provided herein are engineered T cells, expressing a chimeric receptor comprising an antigen-binding domain fused to an endogenous invariant CD3 chain of the immunoglobulin superfamily (invariant CD3-IgSF). In some embodiments, the engineered T cells contain a modified invariant CD3-IgSF chain locus that encodes the chimeric receptor. Also provided are cell compositions containing the engineered T cells, nucleic acids for engineering cells, and methods, kits and articles of manufacture for producing the engineered cells, such as by targeting a transgene encoding a portion of a chimeric receptor for integration into an invariant CD3-IgSF chain genomic locus. In some embodiments, the engineered cells, e.g. T cells, can be used in connection with cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered cells.
    Type: Application
    Filed: November 3, 2021
    Publication date: December 14, 2023
    Applicant: Juno Therapeutics, Inc.
    Inventors: Mateusz Pawel POLTORAK, Lothar GERMEROTH, Christian STEMBERGER
  • Publication number: 20230398149
    Abstract: Provided herein are uses of chimeric antigen receptors (CARs) for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma). In addition, an optimal washout period for commencing a therapy for the treatment of a condition in a subject after a prior exposure can be determined by receiving, for each of a plurality of subjects, prior treatment history data. Left-censored data can then be derived from the prior treatment history data for each of the subjects that includes a washout period and event or censor. A time scale of the left-censored treatment data is then inverted to result in right-censored treatment data. The right-censored treatment data is then applied to a time-to-event (TTE) model that associates one or more variables of interest with a time since exposure to the prior exposure. A maximally selected log-rank statistic across a plurality of cutoffs within a pre-defined percentile range is computed for continuous variables within the one or more variables of interest.
    Type: Application
    Filed: November 3, 2021
    Publication date: December 14, 2023
    Applicants: Celgene Corporation, Juno Therapeutics, Inc.
    Inventors: Julie Ann RYTLEWSKI, Afshin MASHADI-HOSSEIN, Timothy CAMPBELL, Jaymes FULLER